| 000 | 01316 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517131718.0 | ||
| 264 | 0 | _c20180309 | |
| 008 | 201803s 0 0 spa d | ||
| 022 | _a1576-6578 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRodriguez-Gomez, D | |
| 245 | 0 | 0 |
_a[Clinical and immunological improvement of myasthenia gravis following treatment with denosumab]. _h[electronic resource] |
| 260 |
_bRevista de neurologia _c01 2017 |
||
| 300 |
_a47-48 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xadverse effects |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 |
_aAutoantigens _ximmunology |
| 650 | 0 | 4 |
_aDenosumab _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFractures, Spontaneous _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMyasthenia Gravis _xcomplications |
| 650 | 0 | 4 |
_aOsteoporosis _xchemically induced |
| 650 | 0 | 4 |
_aPyridostigmine Bromide _xtherapeutic use |
| 650 | 0 | 4 |
_aRANK Ligand _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Cholinergic _ximmunology |
| 650 | 0 | 4 | _aRemission Induction |
| 700 | 1 | _aGonzalez-Noya, A | |
| 700 | 1 | _aMarnotes-Gonzalez, J | |
| 700 | 1 | _aLorenzo-Vizcaya, A M | |
| 773 | 0 |
_tRevista de neurologia _gvol. 64 _gno. 1 _gp. 47-48 |
|
| 999 |
_c26719211 _d26719211 |
||